Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® ...

Spot check of medicines and equipment in village clinics! The focus is on these 8 items Nature: Bypassing the immune checkpoint IL-18BP to restrict IL-18 immunotherapy has made further progress R&D Da ...

These ailments can be mitigated through the utilization of non-steroidal anti-inflammatory drugs (NSAIDs), antihistamines, immunotherapies such as subcutaneous immunotherapy (SCIT ... potentially ...

A bleach bath should never be used for children without your pediatrician's approval. People with severe cracking ... Allergy drops, also known as sublingual immunotherapy, are generally less ...

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

All the FDA-approved regimens are covered by insurance, said Chaft. Clinicians are most comfortable with pembrolizumab because it is the most widely used immunotherapy in advanced NSCLC ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

WALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug ...

The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea. Research shows that it considerably improves the level of AHI in patients with ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease. The Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd ...

On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...